A consultation was requested for a 25-year-old Caucasian man on the medical service. He was brought to the hospital by the police after he barricaded himself in a motel room, not allowing the housekeeping personnel to come in for days. The patient was found to be agitated and mute. In the emergency department, he was found to have a fever of 40°C, an elevated creatine phosphokinase (CPK), and increased serum osmolality. He was admitted to the general medical floor, and intravenous fluids were given.


Psychotic Symptom Neuroleptic Malignant Syndrome Schizoaffective Disorder Borderline Personality Disorder Haloperidol Decanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994.Google Scholar
  2. Arnold SE. Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Dev Psychopathol 1999;11:439–456.PubMedCrossRefGoogle Scholar
  3. Baptista T, Zarate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5(3):279–299.PubMedCrossRefGoogle Scholar
  4. Burns JK. An evolutionary theory of schizophrenia: cortical connectivity, metarepresentation, and the social brain. Behav Brain Sci 2004;27:831–885.PubMedGoogle Scholar
  5. Cannon TD, Glahn DC, Kim J, et al. Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch Gen Psychiatry 2005;62(10):1071–1080.PubMedCrossRefGoogle Scholar
  6. Crow TJ. Is schizophrenia the price that Homo sapiens pays for language? Schizophr Res 1997;28:127–141.PubMedCrossRefGoogle Scholar
  7. Dickerson F, Kirkpatrick B, Boronow J, Stallings C, Origoni A, Yolken R. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 2006;32(2):396–400.PubMedCrossRefGoogle Scholar
  8. Hamshere ML, Bennett P, Williams N, et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry 2005;62:1081–88.PubMedCrossRefGoogle Scholar
  9. King S, Laplante D, Joober R. Understanding putative risk factors for schizophrenia: retrospective and prospective studies. J Psychiatry Neurosci 2005;30(5):342–348.PubMedGoogle Scholar
  10. Lenior ME, Dingemans PM, Schene AH, Linszen DH. Predictors of the early 5–year course of schizophrenia: a path analysis. Schizophr Bull 2005;31(3):781–791.PubMedCrossRefGoogle Scholar
  11. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 2004;174(1):143–150.CrossRefGoogle Scholar
  12. Marom S, Munitz H, Jones PB, Weizman A, Hermesh H. Expressed emotion: relevance to rehospitalization in schizophrenia over 7 years. Schizophr Bull 2005;31(3):751–758.PubMedCrossRefGoogle Scholar
  13. Messias E, Kirkpatrick B, Bromet E, et al. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry 2004;61(10):985–989.PubMedCrossRefGoogle Scholar
  14. Owen MJ. Genomic approaches to schizophrenia. Clin Ther 2005;27(suppl A):S2–S7.PubMedCrossRefGoogle Scholar
  15. Romanides AJ, Duffy P, Kalivas PW. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience 1999;92:97–106.PubMedCrossRefGoogle Scholar
  16. Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997;7;28(1):1–38.CrossRefGoogle Scholar
  17. Weinberger DR. Genetic mechanisms of psychosis in vivo and postmortem genomics. Clin Ther 2005;27(suppl A):S8–S15.PubMedCrossRefGoogle Scholar


  1. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003;9(5):404–416.PubMedCrossRefGoogle Scholar
  2. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85(1):129–135.PubMedCrossRefGoogle Scholar
  3. Bennett P, Williams N, Segurado R, et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry 2005;62(10):1081–1088.PubMedCrossRefGoogle Scholar
  4. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004;22(2):389–411.PubMedCrossRefGoogle Scholar
  5. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121–2134.PubMedCrossRefGoogle Scholar
  6. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Progr Neuro-Psychopharmacol Biol Psychiatry 2003;27:1113–1123.CrossRefGoogle Scholar
  7. Kendler KS, Karkowski LM, Walsh D, The structure of psychosis latent class analysis of probands from the Roscommon family study. Arch Gen Psychiatry 1998;55:492–499.PubMedCrossRefGoogle Scholar
  8. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(5 suppl 1):S7–14.PubMedCrossRefGoogle Scholar
  9. Nelson RH, Miles JM. The use of orlistat in the treatment of obesity, dyslipidaemia and type 2 diabetes. Expert Opin Pharmacother 2005;6(14):2483–2491.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Hoyle Leigh
    • 1
  1. 1.University of CaliforniaFresnoUSA

Personalised recommendations